New Antifungal Drugs, New Approaches and Vaccines

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

Phase 2

27 March 2017

Pharmacokinetics of the Novel Echinocandin, CD101, in Multiple Animal Species.

27 March 2017

In vitro and in vivo antifungal profile of a novel and long acting inhaled azole, PC945, on Aspergillus fumigatus infection.

13 March 2017

Special Issue: Novel Antifungal Drug Discovery

15 February 2017

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested Against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY (2014) Antifungal Surveillance Program.

15 February 2017

Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties.

23 January 2017

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.

23 January 2017

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Phase 2

15 December 2016

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis (CAMB)

Phase 2

15 December 2016

Discovery of Ibomycin, a Complex Macrolactone that Exerts Antifungal Activity by Impeding Endocytic Trafficking and Membrane Function

8 December 2016